ABBOTT LABORATORIES
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $44.3B | $42.0B | $40.1B | $43.7B | $43.1B |
| Operating income | $8.1B | $6.8B | $6.5B | $8.4B | $8.4B |
| Cost of revenue | $19.3B | $18.7B | $18.0B | $19.1B | $18.5B |
| Cash from operations | $9.6B | $8.6B | $7.3B | $9.6B | $10.5B |
| Capital expenditure | $2.2B | $2.2B | $2.2B | $1.8B | $1.9B |
| Free cash flow | $7.4B | $6.4B | $5.1B | $7.8B | $8.6B |
| Share repurchases | $893.0M | $1.3B | $1.2B | $3.8B | $2.3B |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $86.7B | $81.4B | $73.2B | $74.4B | $75.2B |
Shares outstanding 1.7B · Free float 99.5%
Annual filing data through FY ended December 31, 2025; float as of July 7, 2026.
Recent filings
- April 29, 2026 10-Q
- April 27, 2026 8-K
- April 17, 2026 8-K
- April 16, 2026 8-K
- March 23, 2026 8-K
- March 9, 2026 8-K
- February 26, 2026 8-K
- February 20, 2026 10-K